| E2 | Estrogen |
| ER | Estrogen receptor |
| P4 | Progesterone |
| PR | Progesterone receptor |
| TNBC | Triple negative breast cancer |
| WHI | Women’s health initiative |
| HRT | Hormone replacement therapy |
| HER2 | Human epidermal growth factor receptor 2 |
| MPA | Medroxyprogesterone acetate |
| RANKL | Receptor activator of nuclear factor kappa-B ligand |
| RANK | Receptor activator of nuclear factor kappa-B |
| CCND1 | Cyclin D1 |
| HRE | Hormone response element |
| PRE | Progesterone response element |
| EGFR | Epidermal growth factor receptor |
| MAPK | Mitogen activated protein kinase |
| STAT | Signal transducer and activator of transcription |
| mPR | Membrane progesterone receptor |
| GPCR | G protein coupled receptor |
| PAQR | Progestin and adipoQ receptor |
| MAPR | Membrane associated progesterone receptor |
| PGRMC1 | Progesterone receptor membrane component 1 |
| PGRMC2 | Progesterone receptor membrane component 2 |
| GLI-1 | Glioma associated oncogene homolog 1 |
| NF-kB | Nuclear factor kappa B |
| OVX | Ovariectomized |
| ACI | August copenhagen irish |
| SPRM | Selective progesterone receptor modulator |
| TPA | Telapristone acetate |
| NET | Norethisterone |
| CK2 | Casein kinase 2 |
| 5αP | 5α-dihydroprogesterone |
| 3αHP | 3α-dihydroprogesterone |